{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:27:47Z","timestamp":1784921267980,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004055","name":"King Fahd University of Petroleum and Minerals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004055","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The incidence of malignant melanoma has rapidly increased in the last two decades. There are many challenges associated with the current conventional therapies, including tumour size and location, the specificity of treatments, tumour resistance, non-mutually exclusive mutations, drug resistance, and many adverse side effects. Due to conventional therapies having several limitations, we have explored an alternative therapy such as nano-clays; nano-sized natural materials originating from clay fraction of the soil. Recently, clay nanoparticles have increasingly been used as a drug carrier for cancer treatment due to their high absorption, ability to engulf microbes, and low toxicity. In this study, we evaluated the effects of a nano-clays mix on melanoma cell proliferation and cell viability in vitro and melanoma growth in vivo xenograft animal model. The in vitro study revealed that nano-clay treatments significantly reduced melanoma cell proliferation and cell viability in a dosage-dependent manner. The in vivo tumour xenograft model demonstrated that nano-clay mix treatment led to significantly reduced tumour size and weight, decreased tumour cell mitosis, and induced tumour necrosis. These processes owe to the most probable changes in the membrane potential of the cancer cells once nano-clays bind with the former through the high non-specific adhesion characteristic of the cancer cells. As the data suggest an important role of nano-clays as an inhibitor of melanoma cell proliferation and survival, these prove to be a natural and effective medicine for the treatment of melanoma. The proven compatibility of nano-clays with the human cells with little side-effects makes them a highly preferred choice for the treatment of melanoma and probably other types of cancers.<\/jats:p>","DOI":"10.1038\/s41598-021-82441-8","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T13:21:09Z","timestamp":1612272069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Melanoma treatment via non-specific adhesion of cancer cells using charged nano-clays in pre-clinical studies"],"prefix":"10.1038","volume":"11","author":[{"given":"Sahel N.","family":"Abduljauwad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib-ur-Rehman","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Moy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"82441_CR1","first-page":"2019","volume-title":"Cancer Facts and Figures 2018","author":"American Cancer Society","year":"2019","unstructured":"American Cancer Society. Cancer Facts and Figures 2018 2019 (American Cancer Society, Atlanta, 2019)."},{"issue":"11","key":"82441_CR2","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1055\/s-0030-1250186","volume":"76","author":"WW Hsiao","year":"2010","unstructured":"Hsiao, W. W. & Liu, L. The role of traditional Chinese herbal medicines in cancer therapy\u2014From TCM theory to mechanistic insights. Planta Med. 76(11), 1118\u20131131 (2010).","journal-title":"Planta Med."},{"issue":"13","key":"82441_CR3","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","volume":"16","author":"JJ Grob","year":"2015","unstructured":"Grob, J. J. et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): Results of a phase 3, open-label, randomised trial. Lancet Oncol. 16(13), 1389\u20131398 (2015).","journal-title":"Lancet Oncol."},{"issue":"7","key":"82441_CR4","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.ejca.2013.01.015","volume":"49","author":"S da Rocha Dias","year":"2013","unstructured":"da Rocha Dias, S. et al. The European Medicines Agency review of vemurafenib (Zelboraf) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur. J. Cancer 49(7), 1654\u20131661 (2013).","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"82441_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/pcmr.12475","volume":"29","author":"G Merlino","year":"2016","unstructured":"Merlino, G. et al. The state of melanoma: Challenges and opportunities. Pigment Cell Melanoma Res. 29(4), 404\u2013416. https:\/\/doi.org\/10.1111\/pcmr.12475 (2016).","journal-title":"Pigment Cell Melanoma Res."},{"issue":"4","key":"82441_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1520\/GTJ10287J","volume":"16","author":"SN Abduljauwad","year":"1993","unstructured":"Abduljauwad, S. N. & Al-Sulaimani, G. J. Determination of swell potential of Al-Qatif clay. Geotech. Test J. ASTM 16(4), 469\u2013484 (1993).","journal-title":"Geotech. Test J. ASTM"},{"issue":"1","key":"82441_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1680\/geot.1998.48.1.103","volume":"48","author":"SN Abduljauwad","year":"1997","unstructured":"Abduljauwad, S. N., Al-Sulaimani, G. J., Basunbul, I. A. & Al-Buraim, I. Laboratory and field studies of response of structures to heave of expansive clay. Geotechnique 48(1), 103\u2013121 (1997).","journal-title":"Geotechnique"},{"issue":"6","key":"82441_CR8","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1061\/(ASCE)1090-0241(2000)126:6(538)","volume":"126","author":"S Azam","year":"2000","unstructured":"Azam, S. & Abduljauwad, S. N. Influence of gypsification on engineering behavior of expansive clay. ASCE J. Geotech. Geoenviron. Eng. 126(6), 538 (2000).","journal-title":"ASCE J. Geotech. Geoenviron. Eng."},{"issue":"8","key":"82441_CR9","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1007\/s12274-017-1466-x","volume":"10","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. Intercalated 2D nanoclay for emerging drug delivery in cancer therapy. Nano Res. 10(8), 2633\u20132643 (2017).","journal-title":"Nano Res."},{"key":"82441_CR10","unstructured":"Chianelli, R. R. & Das, S. U.S. Patent No. 8563595 (U.S. Patent and Trademark Office, Washington, DC, 2013)."},{"key":"82441_CR11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.clay.2014.09.020","volume":"101","author":"S Han","year":"2014","unstructured":"Han, S. et al. Targeting of fluorescent palygorskite polyethyleneimine nanocomposite to cancer cells. Appl. Clay Sci. 101, 567\u2013573 (2014).","journal-title":"Appl. Clay Sci."},{"issue":"4","key":"82441_CR12","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.biomaterials.2007.09.038","volume":"29","author":"B Sun","year":"2008","unstructured":"Sun, B., Ranganathan, B. & Feng, S. S. Multifunctional poly (D, l-lactide-coglycolide)\/ montmorillonite (PLGA\/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 29(4), 475\u2013486 (2008).","journal-title":"Biomaterials"},{"issue":"9","key":"82441_CR13","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/S0142-9612(01)00325-8","volume":"23","author":"FH Lin","year":"2002","unstructured":"Lin, F. H. et al. A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier. Biomaterials 23(9), 1981\u20131987 (2002).","journal-title":"Biomaterials"},{"issue":"suppl 3","key":"82441_CR14","doi-asserted-by":"publisher","first-page":"B120","DOI":"10.1179\/1753555714Y.0000000174","volume":"29","author":"C Bothiraja","year":"2014","unstructured":"Bothiraja, C., Thorat, U. H., Pawar, A. P. & Shaikh, K. S. Chitosan coated layered clay montmorillonite nanocomposites modulate oral delivery of paclitaxel in colonic cancer. Mater. Technol. 29(suppl 3), B120\u2013B126 (2014).","journal-title":"Mater. Technol."},{"issue":"1","key":"82441_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ejps.2012.04.009","volume":"47","author":"BD Kevadiya","year":"2012","unstructured":"Kevadiya, B. D. et al. Montmorillonite\/poly-(\u03b5-caprolactone) composites as versatile layered material: Reservoirs for anti-cancer drug and controlled release property. Eur. J. Pharm. Sci. 47(1), 265\u2013272 (2012).","journal-title":"Eur. J. Pharm. Sci."},{"issue":"9","key":"82441_CR16","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/cjoc.201200657","volume":"30","author":"MY Guo","year":"2012","unstructured":"Guo, M. Y. et al. Halloysite nanotubes, a multifunctional nanovehicle for anticancer drug delivery. Chin. J. Chem. 30(9), 2115\u20132120 (2012).","journal-title":"Chin. J. Chem."},{"key":"82441_CR17","unstructured":"Mart\u00ednez, C. D. Cationic clays upon cancer therapy. Virtual Multidisciplinary Conference QUAESTI, 16\u201320 (2013)."},{"key":"82441_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/0169-1317(95)00029-4","volume":"10","author":"J Konta","year":"1995","unstructured":"Konta, J. Clay and man: Clay raw materials in the service of man. Appl. Clay Sci. 10, 275\u2013335 (1995).","journal-title":"Appl. Clay Sci."},{"key":"82441_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0169-1317(00)00016-8","volume":"17","author":"HH Murray","year":"2000","unstructured":"Murray, H. H. Traditional and new applications for kaolin, smectite, and palygorskite: A general overview. Appl. Clay Sci. 17, 207\u2013221 (2000).","journal-title":"Appl. Clay Sci."},{"key":"82441_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.clay.2006.06.013","volume":"36","author":"C Volzone","year":"2007","unstructured":"Volzone, C. Retention of pollutant gases: Comparison between clay minerals and their modified products. Appl. Clay Sci. 36, 191\u2013196 (2007).","journal-title":"Appl. Clay Sci."},{"key":"82441_CR21","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/S0142-9612(01)00325-8","volume":"23","author":"FH Lin","year":"2002","unstructured":"Lin, F. H. et al. A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier. Biomaterials 23, 1981\u20131987 (2002).","journal-title":"Biomaterials"},{"issue":"30","key":"82441_CR22","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.1016\/j.biomaterials.2005.03.021","volume":"26","author":"Y Dong","year":"2005","unstructured":"Dong, Y. & Feng, S. S. Poly (d, l-lactide-coglycolide)\/montmorillonite nanoparticles for oral delivery of anti-cancer drugs. Biomaterials 26(30), 6068\u20136076 (2005).","journal-title":"Biomaterials"},{"key":"82441_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2147\/IJN.S95611","volume":"11","author":"G Choi","year":"2016","unstructured":"Choi, G. et al. Anionic clay as the drug delivery vehicle: Tumour targeting function of layered double hydroxide-methotrexate nanohybrid in C33A orthotopic cervical cancer model. Int. J. Nanomed 11, 337\u2013348. https:\/\/doi.org\/10.2147\/IJN.S95611 (2016).","journal-title":"Int. J. Nanomed"},{"issue":"1","key":"82441_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1180\/clm.2018.42018","volume":"53","author":"F Hosseini","year":"2018","unstructured":"Hosseini, F., Hosseini, F., Jafari, S. M. & Taheri, A. Bentonite nanoclay-based drug-delivery systems for treating melanoma. Clay Miner. 53(1), 53\u201363. https:\/\/doi.org\/10.1180\/clm.2018.42018 (2018).","journal-title":"Clay Miner."},{"key":"82441_CR25","volume-title":"Applications of Nanocomposite Materials in Drug Delivery. A Volume in Woodhead Publishing Series in Biomaterials","author":"IAA Mohammad","year":"2018","unstructured":"Mohammad, I. A. A. Applications of Nanocomposite Materials in Drug Delivery. A Volume in Woodhead Publishing Series in Biomaterials (Woodhead Publishing, India, 2018)."},{"key":"82441_CR26","doi-asserted-by":"publisher","first-page":"33335","DOI":"10.1038\/srep33335","volume":"6","author":"Y Zhang","year":"2016","unstructured":"Zhang, Y. et al. Emerging integrated nanoclay-facilitated drug delivery system for papillary thyroid cancer therapy. Sci. Rep. 6, 33335. https:\/\/doi.org\/10.1038\/srep33335 (2016).","journal-title":"Sci. Rep."},{"key":"82441_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/biot.201900055","volume":"1","author":"E Naumenko","year":"2019","unstructured":"Naumenko, E. & Fakhrullin, R. Halloysite nanoclay\/biopolymers composite materials in tissue engineering. Biotechnol. J. 1, 1. https:\/\/doi.org\/10.1002\/biot.201900055 (2019).","journal-title":"Biotechnol. J."},{"key":"82441_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clay.2018.12.016","author":"E Tarasova","year":"2018","unstructured":"Tarasova, E., Naumenko, E., Rozhina, E., Akhatova, F. & Fakhrullin, R. Cytocompatibility and uptake of polycations-modified halloysite clay nanotubes. Appl. Clay Sci. https:\/\/doi.org\/10.1016\/j.clay.2018.12.016 (2018).","journal-title":"Appl. Clay Sci."},{"key":"82441_CR29","unstructured":"The Clay Minerals Society. http:\/\/www.clays.org\/sourceclays_data.html (2017)."},{"key":"82441_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42498-y","author":"SN Abduljauwad","year":"2019","unstructured":"Abduljauwad, S. N. & Ahmed, H. Enhancing cancer cell adhesion with clay nanoparticles for countering metastasis. Nat. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-019-42498-y (2019).","journal-title":"Nat. Sci. Rep."},{"issue":"5","key":"82441_CR31","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1346\/CCMN.2001.0490511","volume":"49","author":"W Wu","year":"2001","unstructured":"Wu, W. Baseline studies of the clay minerals society source clays: Colloid and surface phenomena. Clays Clay Miner. 49(5), 446\u2013452 (2001).","journal-title":"Clays Clay Miner."},{"key":"82441_CR32","unstructured":"ASTM D7928. Standard Test Method for Particle-Size Distribution (Gradation) of Fine-Grained Soils Using the Sedimentation (Hydrometer) Analysis (ASTM International, West Conshohocken, 2017)."},{"key":"82441_CR33","unstructured":"Cure, J. C. Cancer an electrical phenomenon. Resonant 1(1) (1991)."},{"key":"82441_CR34","volume-title":"Cell Adhesions: Fundamentals and Biotechnological Applications","author":"MA Hjortso","year":"1995","unstructured":"Hjortso, M. A. & Roos, J. W. Cell Adhesions: Fundamentals and Biotechnological Applications (Marcel Deker, New York, 1995)."},{"key":"82441_CR35","unstructured":"Cure, J. C. On the electrical characteristics of cancer. Paper presented at the Second International Congress of Electrochemical Treatment of Cancer, Jupiter (1995)."},{"issue":"3","key":"82441_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1046\/j.1359-4117.2002.01031.x","volume":"2","author":"HF Acevedo","year":"2002","unstructured":"Acevedo, H. F. Human chorionic gonadotropin (hCG), the hormone of life and death: A review. J. Exp. Ther. Oncol. 2(3), 133\u2013145 (2002).","journal-title":"J. Exp. Ther. Oncol."},{"issue":"8","key":"82441_CR37","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/1097-0142(19951015)76:8<1467::AID-CNCR2820760826>3.0.CO;2-A","volume":"6","author":"HF Acevedo","year":"1995","unstructured":"Acevedo, H. F., Tong, J. Y. & Hartsock, R. J. Human chorionic gonadotropin-beta subunit gene expression in cultured human fetal and cancer cells of different types and origins. Cancer 6(8), 1467\u20131475 (1995).","journal-title":"Cancer"},{"key":"82441_CR38","unstructured":"Acevedo, H., Gonzalez, N. & Moss, R. Trophoblastic Hormones and Cancer: A Breakthrough in Treatment? Comprehensive Cancer Care Conference, Session 205, June 13, 1998."},{"issue":"4","key":"82441_CR39","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.resmic.2005.01.007","volume":"156","author":"N Cerca","year":"2005","unstructured":"Cerca, N., Pier, G. B., Vilanova, M., Oliveira, R. & Azeredo, J. Quantitative analysis of adhesion and biofilm formation on hydrophilic and hydrophobic surfaces of clinical isolates of Staphylococcusepidermidis. Res. Microbiol. 156(4), 506\u2013514 (2005).","journal-title":"Res. Microbiol."},{"key":"82441_CR40","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1159\/000224545","volume":"24","author":"CD Cone","year":"1970","unstructured":"Cone, C. D. Variation of the transmembrane potential level as a basic mechanism of mitosis control. Oncology 24, 438\u2013470 (1970).","journal-title":"Oncology"},{"key":"82441_CR41","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1749-6632.1974.tb26808.x","volume":"238","author":"CD Cone","year":"1975","unstructured":"Cone, C. D. The role of surface electrical transmembrane potential in normal and malignant mitogenesis. Ann. N.Y. Acad. Sci. 238, 420\u2013435 (1975).","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"82441_CR42","volume-title":"Transmembrane Potentials and Characteristics of Immune and Tumour Cells","author":"CD Cone","year":"1985","unstructured":"Cone, C. D. Transmembrane Potentials and Characteristics of Immune and Tumour Cells (CRC Press, Boca Raton, 1985)."},{"issue":"5","key":"82441_CR43","first-page":"465","volume":"10","author":"FW Cope","year":"1978","unstructured":"Cope, F. W. A medical application of the Ling Association-Induction Hypothesis: The high potassium, low sodium diet of the Gerson cancer therapy. Physiol. Chem. Phys. 10(5), 465\u2013468 (1978).","journal-title":"Physiol. Chem. Phys."},{"key":"82441_CR44","unstructured":"Alexander, A. D. Calcium 2-AEP and calcium orotate found essential in the prevention and treatment of osteoporosis. INI Newsletter (1997)."},{"key":"82441_CR45","volume-title":"The Curious Man: The Life and Works of Dr. Hans Nieper","author":"HA Nieper","year":"1999","unstructured":"Nieper, H. A., Alexander, A. D. & Eagle-Ogden, G. S. The Curious Man: The Life and Works of Dr. Hans Nieper (Avery Publishing Group, Garden City Park, 1999)."},{"key":"82441_CR46","doi-asserted-by":"publisher","first-page":"29467","DOI":"10.1039\/C4RA16945J","volume":"5","author":"M Ghadiri","year":"2015","unstructured":"Ghadiri, M., Chrzanowskia, W. & Rohanizadeh, R. Biomedical applications of cationic clay minerals. RSC Adv. 5, 29467 (2015).","journal-title":"RSC Adv."},{"key":"82441_CR47","doi-asserted-by":"publisher","first-page":"1805730","DOI":"10.1002\/adma.201805730","volume":"31","author":"G Yang","year":"2019","unstructured":"Yang, G., Phua, S. G. F., Bindra, A. K. & Zhao, Y. Degradability and clearance of inorganic nanoparticles for biomedical applications. Adv. Mater. 31, 1805730. https:\/\/doi.org\/10.1002\/adma.201805730 (2019).","journal-title":"Adv. Mater."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82441-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82441-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82441-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T02:50:43Z","timestamp":1670035843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82441-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["82441"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-82441-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"assertion":[{"value":"23 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2737"}}